| Literature DB >> 31379247 |
Krzysztof Plesiński1, Piotr Adamczyk2, Elżbieta Świętochowska3, Aurelia Morawiec-Knysak4, Aleksandra Gliwińska4, Omar Bjanid2, Maria Szczepańska2.
Abstract
BACKGROUND: The most common disease associated with the presence of kidney cysts in the population is autosomal dominant polycystic kidney disease (ADPKD), which finally leads to end-stage renal disease.Entities:
Keywords: Angiotensinogen; autosomal dominant polycystic kidney disease; chronic kidney disease; interleukin 18; renal cysts
Mesh:
Substances:
Year: 2019 PMID: 31379247 PMCID: PMC6683321 DOI: 10.1177/1470320319862662
Source DB: PubMed Journal: J Renin Angiotensin Aldosterone Syst ISSN: 1470-3203 Impact factor: 1.636
Characteristics of examined children with renal cysts and controls.
| Parameter | Children with kidney cysts | Control group ( | ||||
|---|---|---|---|---|---|---|
| Whole group ( | ADPKD ( | Non-ADPKD ( | Girls ( | Boys | ||
|
| 10.9 ± 4.9 (1.9–19.8) | 10.9 ± 5.1 (3.4–19.8) | 11.0 ± 5.0 (1.9–18.7) | 10.8 ± 4.6 (3.4–18.7) | 11.1 ± 5.6 (1.9–19.8) | 8.8 ± 3.9 (1.8–17.2) |
|
| 142.3 ± 24.9 (80–184.5) | 141.7 ± 26.0 (97–184.5) | 142.9 ± 24.3 (80–176) | 142.1 ± 22.5 (97–173) | 142.5 ± 28.7 (80–184.5) | 130.8 ± 22.7 (82–172) |
|
| −0.03 ± 1.12 (–2.97–2.24) | −0.05 ± 1.0 (–2.97–1.8) | −0.02 ± 1.2 (–1.9–2.2) | 0.2 ± 1.2 (–2.97–1.81) | −0.3 ± 1.0 (–1.9–2.2) | −0.4 ± 0.9 (–1.9–2.0) |
|
| 40.7 ± 17.8 (11–78) | 41.7 ± 19.8 (13–78) | 39.6 ± 16.0 (11–69) | 40.5 ± 17.6 (13–78) | 41.0 ± 18.8 (11–70) | 33 ± 16.1 (9.7–63) |
|
| 0.13 ± 1.09 (–3.2–2.07) | 0.2 ± 1.2 (–3.2–1.9) | 0.05 ± 1.0 (–1.3–2.1) | 0.2 ± 1.2 (–3.2–1.91) | −0.06 ± 1.0 (–1.3–2.07) | −0.003 ± 1.0 (–1.6–1.8) |
|
| 18.9 ± 3.29 (13.5–28.7) | 19.3 ± 4.0 (13.5–28.7) | 18.4 ± 2.4 (14.4–22.3) | 18.9 ± 3.7 (13.5–28.7) | 18.9 ± 2.7 (14.8–23.4) | 18.0 ± 3.4 (14.2–26.6) |
|
| 0.23 ± 0.93 (–1.38–2.02) | 0.3 ± 1.1 (–1.4–2.02) | 0.2 ± 0.8 (–1.3–1.7) | 0.3 ± 1.0 (–1.38–2.02) | 0.2 ± 0.9 (–1.3–1.7) | 0.7 ± 2.1 (–1.5–8.8) |
|
| 109.8 ± 13.3 (90–137) | 111.6 ± 14.0 (90–137) | 107.9 ± 12.6 (90–130) | 111.4 ± 13.3 (90–137) | 107.4 ± 13.4 (90–130) | |
|
| 64.9 ± 8.9 (45–84) | 66.7 ± 10.5 (45–84) | 63.1 ± 6.8 (55–75) | 66.5 ± 9.2 (50–84) | 62.8 ± 8.3 (45–77) | |
|
| 79.9 ± 9.8 (61.7–98.3) | 81.7 ± 11.1 (61.7–98.3) | 78.0 ± 8.2 (66.7–93.3) | 81.5 ± 10.0 (63.3–98.3) | 77.7 ± 9.3 (61.7–93.3) | |
|
| 0.58 ± 1.0 (–1.22–2.63) | 0.8 ± 1.1 (–0.8–2.6) | 0.4 ± 0.9 (–1.2–1.6) | 0.8 ± 1.0 (–0.84–2.63) | 0.3 ± 0.9 (–1.2–1.8) | |
|
| 0.39 ± 0.7 (–0.95–2.07) | 0.5 ± 0.8 (–0.9–2.07) | 0.2 ± 0.7 (–0.8–2.0) | 0.5 ± 0.7 (–0.6–2.07) | 0.2 ± 0.8 (–0.9–2.0) | |
Data are presented as mean ± standard deviation (minimum–maximum).
BW: body weight; SDS: standard deviation score; BMI: Body Mass Index; SYS: systolic arterial pressure; DIA: diastolic arterial pressure; MAP: mean arterial pressure; ADPKD: autosomal dominant polycystic kidney disease.
Laboratory tests and eGFR value in children with renal cysts.
| Parameter | Wholegroup ( | ADPKD ( | Non-ADPKD ( | Girls ( | Boys ( |
|---|---|---|---|---|---|
|
| 140.1 ± 2.2 (134–143) | 140.0 ± 2.5 (134–143) | 140.2 ± 1.7 (136–143) | 140.3 ± 1.7 (136–143) | 139.8 ± 2.8 (134–143) |
|
| 4.5 ± 0.4 (4.0–5.4) | 4.4 ± 0.4 (3.98–5.1) | 4.5 ± 0.3 (4.0–5.4) | 4.4 ± 0.3 (3.98–5.1) | 4.5 ± 0.4 (4.0–5.4) |
|
| 48.0 ± 15.6 (22–77) | 48.3 ± 17.5 (22–77) | 47.8 ± 13.7 (29–73) | 45.8 ± 13.7 (22–69) | 51.25 ± 17.9 (27–77) |
|
| 266.2 ± 67.8 (134–370) | 267.4 ± 66.5 (150–368) | 264.9 ± 71.0 (134–370) | 253.4 ± 65.0 (134–351) | 284.4 ± 69.7 (151–370) |
|
| 4.3 ± 1.3 (2.4–6.8) | 4.4 ± 1.4 (2.4–6.8) | 4.2 ± 1.2 (2.5–6.1) | 4.16 ± 1.25 (2.4–6.6) | 4.4 ± 1.3 (2.5–6.8) |
|
| 119.8 ± 32.7 (38.2–179.3) | 121.5 ± 35.0 (38.2–176.0) | 117.9 ± 30.8 (47.8–179.3) | 115.9 ± 28.25 (38.2–156.2) | 125.3 ± 38.5 (47.8–179.3) |
Data are presented as mean ± standard deviation (minimum–maximum).
For all comparisons p > 0.05.
eGFR: glomerular filtration rate; ADPKD: autosomal dominant polycystic kidney disease.
Figure 1.Concentration of AGT in (a) serum and (b) urine, and (c) AGT (serum)/BMI ratio in children from the whole study group, control group and subgroups of the study group.
AGT: angiotensinogen; ADPKD: autosomal dominant polycystic kidney disease; BMI: body mass index.
Figure 2.Concentration of IL-18 in (a) serum and (b) urine, and (c) IL-18 (serum)/BMI ratio in children from the whole study group, control group and subgroups of the study group.
IL-18: interleukin 18; ADPKD: autosomal dominant polycystic kidney disease; BMI: body mass index.
Evaluation of the correlation between the tested markers and the results of anthropometric measurements, biochemical parameters and BP values.
| Parameter | Children with kidney cysts | |||
|---|---|---|---|---|
| AGT (S) | AGT (U) | IL-18 (S) | IL-18 (U) | |
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
BP: blood pressure; BW: body weight; SDS: standard deviation score; BMI: Body Mass Index; SYS: systolic arterial pressure; DIA: diastolic arterial pressure; MAP: mean arterial pressure; AGT: angiotensinogen; IL-18: interleukin 18; S: serum; U: urine.